First in class, multi-specific CD73/PD-1 inhibitor DFC, exhibited robust anti-tumor activity in humanized mouse models of colorectal cancer at low doses
CD73/PD-1 DFC demonstrated superior anti-tumor activity to CD73 and PD-1 monotherapies
“We are thrilled to be presenting promising preclinical data on our novel multi-specific DFC in colorectal cancer for the first time at ESMO-IO this year,” said
Presentation details are summarized below:
Title: Discovery of a Novel, Dual CD73 & PD-1 Targeting Multi-specific Drug Fc-Conjugate (DFC) for the Treatment of Cancer
Presenter: James Levin, Ph.D.,
Date and Time:
Key highlights:
- CD73/PD-1 DFC is a potent inhibitor of hCD73 and hPD-1
- DFC reduced tumor growth by 56% at 1mg/kg and >70% at 3mg/kg doses
- DFC demonstrated superior activity to a pembrolizumab biosimilar antibody and a matched CD73 DFC at 1/3 the dose of the respective monotherapies
Title: Discovery of CBO421, a First-in-Class Drug Fc-Conjugate (DFC), Targeting CD73 in Cancer
Presenter: Simon Döhrmann, Ph.D.,
Date and Time:
Key highlights:
- CBO421 is a potent, AMP-competitive inhibitor of CD73 that demonstrates a differentiated in vitro activity profile across several assays compared with small molecule and antibody inhibitors of CD73 in clinical development
- The in vitro potency, multiple mechanisms of action, and favorable pharmacokinetics profile of CBO421 translated to antitumor efficacy in monotherapy and in combination with PD-1 therapy
Cidara is currently advancing its dual CD73/PD-1 inhibitor DFC and CBO421 in preclinical studies. The company plans to file an investigational new drug (IND) application in mid-2024 for CBO421.
About
Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “anticipates,” “believe,” “could,” “expect,” “may,” “plan” or “will”. Forward-looking statements in this release include, but are not limited to, statements related to whether nonclinical data generated for CBO421 to date will be predictive of activity in humans, whether pharmacokinetics, toxicology, and other nonclinical data being generated for CBO421 will be adequate to support an IND filing with the FDA, and whether a combination CD73 and PD-1 DFC will progress to further nonclinical development. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements. These and other risks are identified under the caption “Risk Factors” in Cidara’s Annual Report on Form 10-K for the fiscal year ended
INVESTOR CONTACT:
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
(646) 970-4682
veames@lifescicomms.com
Source:
2023 GlobeNewswire, Inc., source